FY2029 EPS Estimate for Vir Biotechnology Lowered by Analyst

Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - Equities research analysts at HC Wainwright lowered their FY2029 earnings estimates for Vir Biotechnology in a report released on Friday, January 31st. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of $2.25 for the year, down from their previous estimate of $2.56. HC Wainwright has a "Buy" rating and a $110.00 price target on the stock. The consensus estimate for Vir Biotechnology's current full-year earnings is ($3.92) per share.

Several other brokerages also recently issued reports on VIR. Leerink Partners increased their price target on Vir Biotechnology from $18.00 to $20.00 and gave the company an "outperform" rating in a report on Monday, January 13th. JPMorgan Chase & Co. raised their target price on Vir Biotechnology from $10.00 to $14.00 and gave the company a "neutral" rating in a report on Thursday, January 9th. Morgan Stanley raised Vir Biotechnology from an "equal weight" rating to an "overweight" rating and boosted their price target for the stock from $10.00 to $20.00 in a research report on Thursday, January 9th. Barclays lowered their price objective on shares of Vir Biotechnology from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Monday, November 4th. Finally, Needham & Company LLC reissued a "buy" rating and set a $19.00 target price on shares of Vir Biotechnology in a research report on Wednesday, November 20th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, Vir Biotechnology presently has a consensus rating of "Moderate Buy" and a consensus price target of $34.83.

Vir Biotechnology Stock Up 1.8 %

Shares of VIR stock traded up $0.18 during mid-day trading on Monday, reaching $10.23. The company's stock had a trading volume of 1,615,858 shares, compared to its average volume of 3,340,978. The firm has a market capitalization of $1.41 billion, a PE ratio of -2.61 and a beta of 0.63. The company's 50 day simple moving average is $8.99 and its 200-day simple moving average is $8.52. Vir Biotechnology has a 12-month low of $6.56 and a 12-month high of $14.45.

Insider Buying and Selling at Vir Biotechnology

In other Vir Biotechnology news, Director Vicki L. Sato sold 10,960 shares of the stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $12.52, for a total transaction of $137,219.20. Following the transaction, the director now directly owns 1,312,391 shares in the company, valued at $16,431,135.32. This represents a 0.83 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 15.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Vir Biotechnology

A number of institutional investors have recently modified their holdings of the stock. Rhumbline Advisers grew its stake in Vir Biotechnology by 0.5% in the fourth quarter. Rhumbline Advisers now owns 236,681 shares of the company's stock worth $1,737,000 after purchasing an additional 1,288 shares in the last quarter. Blue Trust Inc. lifted its holdings in Vir Biotechnology by 143.5% during the 3rd quarter. Blue Trust Inc. now owns 3,989 shares of the company's stock worth $30,000 after buying an additional 2,351 shares during the last quarter. Public Sector Pension Investment Board grew its position in shares of Vir Biotechnology by 1.4% in the 3rd quarter. Public Sector Pension Investment Board now owns 194,208 shares of the company's stock worth $1,455,000 after acquiring an additional 2,600 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Vir Biotechnology by 11.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 29,202 shares of the company's stock valued at $214,000 after acquiring an additional 2,922 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its position in shares of Vir Biotechnology by 7.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 48,987 shares of the company's stock valued at $436,000 after acquiring an additional 3,605 shares in the last quarter. Institutional investors and hedge funds own 65.32% of the company's stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).